Date: 2011-05-17
Type of information: Licensing agreement
Compound: antibody directed against interleukin 3 (IL-3)
Company: SuppreMol (Germany) University of Regensburg(Germany)
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases
Type agreement: licensing
Action mechanism: inhibition of IL-3
Disease: rheumatoid arthritis
Details: SuppreMol has closed an agreement to in-license an antibody directed against interleukin 3 (IL-3), which has been developed by the Molecular Immunology research group led by Prof. Dr. Matthias Mack at the University of Regensburg. Recently, the team of Prof. Mack was able to demonstrate that IL-3 plays an important role in the onset of rheumatoid arthritis, an autoimmune disease characterized by a chronic inflammation of the joints and other organs affecting up to one percent of the population in the industrialized world. Therapy with an antibody-based IL-3 inhibitor, either in early stages or during flares and exacerbations, may provide a new class of treatment for patients suffering from rheumatoid arthritis. The agreement was closed with Bayerische Patentallianz GmbH, the central patent and marketing agency of 28 Bavarian universities and universities of applied sciences.
Financial terms:
Latest news:
